Rep. Waxman Statement on the Supreme Court Ruling in Caraco v. Novo

Apr 17, 2012

Ranking Member Henry A. Waxman released the following statement in response to the Supreme Court’s decision in the Caraco Pharmaceutical v. Novo Nordisk case:

“I welcome the decision by the U.S. Supreme Court on the Caraco v. Novo case.  While the issues in the case may seem arcane, the fact of the matter is that allowing brand companies to exaggerate the breadth of their patent protections in their listings with FDA served as a real block to generics.  I am pleased that the courts unanimously agreed with that view.  This decision is in the interest of American consumers who should have the benefit of competition and lower prices.”

Rep. Waxman filed an amicus brief with the Court in September 2011 that is posted below.

Related Documents: 

Recent News
Rep. Waxman Statement on President Obama’s Nomination for FCC Chairman 05/01/2013
California Democrats Request Grid Operator Plan to Maintain Reliability 04/26/2013
Committee Continues Bipartisan Review of Renewable Fuel Standard with Examination of Agricultural Impacts 04/18/2013
Democratic Leaders Introduce Legislation to Save Taxpayers More Than $140 Billion in Medicare Drug Costs 04/16/2013
FYI: Supplemental Memo on FDA Oversight of Compounding Pharmacies 04/15/2013
Democratic Committee Leaders Request Testimony on Meningitis Outbreak from Academy of Compounding Pharmacists 04/11/2013
Ranking Members Waxman and Rush Renew Request for Hearings on Science of Climate Change 04/09/2013
Rep. Waxman Statement on EPA Proposed Standards for Cleaner Cars and Fuel 03/29/2013
Rep. Waxman Statement on FCC Chairman Genachowski 03/22/2013
Committee Launches Bipartisan Review of Renewable Fuel Standard with White Paper Examining “Blend Wall” Challenges 03/20/2013